House Bill 2075, known as the "Helping Open Pathways to Effective (HOPE) Treatment Act," seeks to promote research on ibogaine, a psychoactive compound that may offer therapeutic benefits for mental health and neurological conditions, including opioid use disorder and PTSD. The bill establishes a new chapter in the Tennessee Code Annotated, Title 33, which outlines the creation of cohorts composed of drug developers, research institutions, and hospitals that can apply to conduct clinical trials for ibogaine. These cohorts must submit proposals to the Department of Mental Health and Substance Abuse Services for funding and approval, and any ibogaine treatment must be supervised by a licensed physician in a healthcare facility.

Furthermore, the bill creates a council on emerging behavioral health treatments to oversee the state's participation in ibogaine research and establishes an emerging behavioral health treatment innovation fund to manage revenue from FDA-approved medications developed through these trials. It also provides liability protection for healthcare providers and researchers involved in ibogaine clinical trials, ensuring they are shielded from criminal liability under state controlled substance laws, provided they comply with federal regulations. The act is set to take effect on July 1, 2026, contingent upon the approval of ibogaine by the United States Food and Drug Administration for medical use.